Unknown

Dataset Information

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments.


ABSTRACT:

Purpose

Targeted tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs) revolutionized the treatment of metastatic renal cell carcinoma (RCC). Efforts to translate these therapies into the adjuvant setting for local and locoregional RCC have been pursued over the past decade. We sought to provide an updated review of the literature regarding adjuvant therapy in RCC, as well as an analysis of patient characteristics that may portend the most favorable responses.

Materials and methods

Using PubMed, Google Scholar, and Wiley Online Library, we reviewed articles between 2000 and 2022. Search terms included "tyrosine kinase inhibitors," "adjuvant," "immunotherapy," and "renal cell carcinoma." The articles included were original and published in English. Informa

SUBMITTER: Boyle JJ 

PROVIDER: S-EPMC9928983 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature